CTRA Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
CTRA is not a strong buy right now for a Beginner long-term investor with $50,000-$100,000 and an impatient entry style. The stock is trading below recent resistance and the trend is mixed-to-soft despite bullish moving averages. With no AI Stock Picker or SwingMax signal, I would not call this an urgent buy today. Wall Street is broadly constructive but split, and the latest quarter shows revenue growth but weaker earnings. Best direct view: hold, not buy, at this moment.
Price is 32.49 after a sharp regular-session drop, sitting just above S2 at 32.093 and below S1 at 33.002. The moving-average structure is bullish overall (SMA_5 > SMA_20 > SMA_200), which supports the longer-term trend, but momentum is not strong: MACD histogram is positive yet contracting, and RSI_6 at 30.864 suggests the stock is near oversold but not yet a clear reversal signal. Near-term chart behavior is weak, and the stock trend model points to only modest next-day upside with a negative one-month outlook.
Recent analyst target increases are a major positive catalyst, with multiple firms raising targets into the $37-$47 range after higher oil-price assumptions. News also indicates the Devon Energy and Coterra all-stock merger has completed, creating a larger-cap shale operator with a strong Delaware Basin position. Sector sentiment has improved on higher oil and gas price expectations, which supports cash-flow potential.
The stock had a large recent drop in the regular session, and the near-term modeled trend is weak over the next month. Scotiabank only rates it Sector Perform, which tempers enthusiasm. Texas Capital and Siebert Williams both downgraded the name to Hold in connection with the merger. The merger completion and S&P 500 replacement event create a transition phase, and the latest quarter showed net income and EPS declining year over year despite higher revenue.
Latest reported quarter: 2026/Q1. Revenue increased 18.11% YoY to 2.381B, which is a solid growth sign. Gross margin improved to 53.38%, up 6.02% YoY, showing better operating efficiency. However, net income fell 9.69% YoY to 466M and EPS declined 10.29% YoY to 0.61, so profitability did not keep pace with sales growth. Overall, the quarter was mixed: better top line and margins, weaker bottom line.
Analyst sentiment is mildly positive but not uniformly bullish. Several firms raised price targets significantly, including Citi to $42 with a Buy rating, Mizuho to $43 with Outperform, Barclays to $37 with Overweight, Piper Sandler to $47 with Overweight, and UBS to $38 with Buy. Morgan Stanley raised its target to $42 but stayed Equal Weight, while Scotiabank moved to $32 with Sector Perform. Recent downgrades from Texas Capital and Siebert Williams to Hold show some caution, especially around the merger. Overall, Wall Street leans constructive, but the view is mixed rather than a clean bullish consensus.
